Introduction
Defects in the DNA mismatch repair (MMR) system cause replication errors or instability in DNA microsatellites. Germline mutations in MMR genes MLH1, MSH2, MSH6, and PMS2 cause the autosomal dominant hereditary disease Lynch syndrome. Over 90% of tumors from patients with this syndrome show high levels of microsatellite instability (MSI-High) (1) . MSI also occurs in 10-15% of sporadic tumors, especially colorectal and endometrial carcinomas, due to hypermethylation of the MLH1 promoter (2) . Screening for defects in the MMR genes has become important for the identification of patients with Lynch Syndrome and has treatment and prognostic significance for patients with sporadic colorectal cancer. Screening for Lynch Syndrome can not only effectively prevent subsequent cancers in the screened individual, but it also can prevent cancer development in relatives who also harbor a germline mutation of a MMR gene.
Traditionally, clinical screening methods to help identify families at risk for Lynch Syndrome included the use of the Amsterdam and Amsterdam II Criteria.
Because these criteria have been thought to lack sensitivity, particularly when an extensive family history is unavailable, the revised Bethesda Criteria were developed. The Bethesda Criteria are more sensitive, focus on the patient medical history and introduced the category of microsatellite instability and tumor morphology into clinical guidelines. However, these criteria do not address patients with endometrial cancer and may fail to identify a large number of mutation carriers that do not meet the clinical criteria (3) individuals at-risk for Lynch Syndrome, several clinical prediction models have been developed to quantify the risk for germline MMR mutations (4) (5) (6) . These have comparable sensitivities to the Bethesda Criteria and can provide quantitative risk assessment (7) . However, such prediction models require subsequent genetic testing and are not helpful in identifying patients with sporadic MSI-High colorectal cancers requiring alternative treatment regimens.
Two tissue-based screening methods used to assess tumors for MMR defects include PCR-based MSI testing and immunohistochemistry. In general, a number of large studies have concluded that MSI and immunohistochemistry have comparable sensitivity and specificity in detecting MMR defects (8) (9) (10) (11) (12) .
Because it is generally associated with lower cost, faster turnaround time, and wider availability in smaller pathology laboratories, some advocate that immunohistochemistry could be used as the sole method of screening in certain cancers (9, (13) (14) (15) (16) .
At our institution we perform both PCR-based MSI and immunohistochemistry concurrently. Immunohistochemistry-MSI analysis discordances have been acknowledged in the research setting, but the frequency and nature of these problems have not been formally examined in a quality assurance fashion in the clinical laboratory. In surgical pathology practice, correlation reviews (cytology-histology and frozen section-final pathology correlations) are commonly used tools for quality assurance (17) . This type of quality assurance review has not been previously applied to the tissue-based approach to MMR testing. Therefore, we examined sources of discordances and problems in tissue based testing to help optimize this approach in our patient population.
Materials and Methods

Patient Population and Study Design
After analysis, and subsequent genetic sequencing and large rearrangement testing for the four most common MMR genes, was also documented.
Molecular Analyses
All immunohistochemistry and PCR-based molecular analyses were performed in CLIA-and College of American Pathology-approved laboratories.
Immunohistochemistry was performed for DNA mismatch repair gene products promoter methylation assay and BRAF V600E mutational testing by pyrosequencing were performed on a subset of cases (20) (21) .
Statistical Analysis
Cancer Research. 
Results
Patient tumor population
From August 2002 to August 2010, 629 patients had tumors analyzed by both immunohistochemistry and microsatellite instability analysis. Twenty-six of these patients had more than one tumor analyzed. Therefore, there are a total of 646 tumor analyses included in this study. The majority of tumors were colorectal adenocarcinomas (88%), followed by endometrial carcinomas (7%) ( Table 1) . Table 2 
Problems -Immunohistochemistry
Problems were identified in ten patients. These problems do not overlap with the discordances presented in Table 4 . The problems were grouped as selection error (n=2), pathologist error in immunohistochemistry interpretation 
Discussion
Because immunohistochemistry is less expensive, more widely available, relatively simple to perform, and thought to be comparable to MSI analysis, a number of studies have advocated the use of immunohistochemistry alone in the initial evaluation for MMR defects (14) (15) (16) 22) . Indeed, we confirm that, in general, concordance between immunohistochemistry and MSI analysis is quite or MS-Stable (28) . MSH6 mutation carriers are especially prone to developing endometrial cancer, and these tumors are not typically MSI-High (29, 30) .
Experience with MSI analysis is even more limited with other cancer types associated with Lynch Syndrome, such as cancers of the ureter, ovary, and small intestine. Thus, concurrent MSI analysis and immunohistochemistry should be performed in patients with these extra-colonic malignancies. 
